文献速递中医内科中药与中成药合理使用

人参治疗气虚型肝癌机制:粪便代谢组与肠道菌群研究

Comprehensive fecal metabolomics and gut microbiota for the evaluation of the mechanism of Panax Ginseng in the treatment of Qi-deficiency liver cancer.
PubMed 文献 · J Ethnopharmacol · 2022-03-24

该研究基于前期药效学评价,采用粪便代谢组学和16S rRNA测序技术,探讨人参有效部位及人参皂苷与多糖协同作用治疗气虚型肝癌的机制。研究筛选出31个药效潜在生物标志物和20个协同潜在生物标志物,涉及6条主要代谢通路,并在属水平发现25种和23种显著差异菌属,Spearman相关分析显示表型、肠道菌群与粪便代谢物间存在复杂潜在关系。

要点

  • 人参有效部位可调节气虚型肝癌的粪便代谢物,涉及胆汁酸、不饱和脂肪酸等通路。
  • 人参皂苷与多糖协同作用可显著改变属水平肠道菌群组成。
  • 表型、肠道菌群与粪便代谢物之间存在复杂相关性,提示多靶点机制。

核心结论

  • 通过粪便内源性代谢物和肠道细菌的变化,初步阐明了人参治疗气虚型肝癌的机制。

研究设计与样本

  • 研究在前期药效学评价基础上,采用粪便代谢组学和16S rRNA测序技术,并结合KEGG数据库和Spearman相关分析。

主要发现

  • 粪便代谢组学筛选出31个药效潜在生物标志物和20个协同潜在生物标志物。
  • 检索到6条主要代谢通路,包括胆汁酸生物合成、不饱和脂肪酸生物合成、色氨酸代谢、花生四烯酸代谢、嘧啶代谢和维生素B6代谢。
  • 属水平上筛选出25种药效显著差异细菌和23种人参皂苷与多糖协同作用显著差异细菌。
  • Spearman相关分析显示表型、肠道菌群和粪便代谢物之间存在复杂潜在关系,主要体现在细菌与胆汁酸、不饱和脂肪酸和吲哚类化合物等粪便代谢物之间。

临床怎么用

  • 本研究为临床利用人参治疗气虚型肝癌提供了代谢和菌群层面的机制线索,但具体应用需结合临床辨证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Qi deficiency liver cancer (QDLC) is an important part of liver cancer research in traditional Chinese medicine (TCM). In the course of its treatment, Panax ginseng is often selected as the main Chinese herbal medicine, and its function has special significance in the tumor treatment of Qi deficiency constitution. However, its mechanism is not clear. AIM OF THE STUDY: The research tried to evaluate the mechanism of Panax ginseng in the treatment of QDLC through fecal metabonomics and gut microbiota on the basis of previous pharmacodynamic evaluation. MATERIALS AND METHODS: Firstly, biomarkers and related metabolic pathways were screened and identified by metabonomics and Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Then, 16S rRNA sequencing technique was used to investigate the composition, β diversity and key differences of gut microbiota. Finally, the relationship among phenotypes, gut microbiota and fecal metabolites was comprehensively analyzed by spearman correlation coefficient. RESULTS: 31 pharmacodynamic potential biomarkers and 20 synergistic potential biomarkers of effective parts of Panax ginseng on QDLC were screened and identified by fecal metabonomics. And then, 6 major metabolic pathways were searched, including bile acid biosynthesis, unsaturated fatty acid biosynthesis, tryptophan metabolism, arachidonic acid metabolism, pyrimidine metabolism, vitamin B6 metabolism. In the study of gut microbiota, at the genus level, 25 species of bacteria with significant differences of effective parts on QDLC and 23 species of bacteria with significant differences of synergistic action of ginsenosides and polysaccharides were screened. In addition, Spearman correlation analysis showed that there was a complex potential relationship among phenotype, gut microbiota and fecal metabolites during the development of QDLC and Panax ginseng intervention, which was mainly reflected in the close potential relationship between bacteria and fecal metabolites such as bile acids, unsaturated fatty acids and indole compounds. CONCLUSION: Through the changes of fecal endogenous metabolites and intestinal bacteria, the mechanism of Panax ginseng on QDLC were preliminarily clarified.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Hou Z, Song F, Xing J, et al. Comprehensive fecal metabolomics and gut microbiota for the evaluation of the mechanism of Panax Ginseng in the treatment of Qi-deficiency liver cancer. J Ethnopharmacol. 2022. PMID: 35341933. doi:10.1016/j.jep.2022.115222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。